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Abstract
Hereditary haemorrhagic telangiectasia or Rendu-Osler-Weber syndrome is a systemic vascular disease with autosomal dominant
inheritance, mucocutaneous telangiectasia, and repeated nasal bleeding due to vascular abnormalities. Hereditary haemorrhagic
telangiectasia may occasionally lead to complications, including arteriovenous malformations and pulmonary hypertension. We
present a case of a 52-year-old female patient with hereditary haemorrhagic telangiectasia who was referred to our hospital for
treatment of pulmonary hypertension. She had been diagnosed with hereditary haemorrhagic telangiectasia during adolescence and
was being followed up. Six months prior to presentation, she had undergone coil embolization for pulmonary haemorrhage due to
pulmonary arteriovenous malformations. She was in World Health Organization functional class IV, with a mean of pulmonary
arterial pressure of 38mmHg, a pulmonary capillary wedge pressure of 10mmHg, and a right atrial pressure of 22mmHg.
A contrast-enhanced computed tomography angiography showed large arteriovenous malformations in the liver. Right heart
catheterization revealed an increase in oxygen saturation in the inferior vena cava between the supra- and infra-hepatic veins,
low pulmonary vascular resistance, and high right atrial pressure. Hence, she was diagnosed with hereditary haemorrhagic
telangiectasia with pulmonary hypertension due to major arteriovenous shunt resulting from arteriovenous malformations in
the liver. Therefore, we considered liver transplantation as an essential treatment option. She underwent cadaveric liver trans-
plantation after a year resulting in dramatic haemodynamic improvement to World Health Organization functional class I. Liver
transplantation is a promising treatment in patients with hereditary haemorrhagic telangiectasia and pulmonary hypertension
resulting from arteriovenous shunt caused by arteriovenous malformations in the liver.
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Case description
A 52-year-old female patient with hereditary haemorrhagic
telangiectasia (HHT) presented with dyspnoea. She had
been diagnosed with HHT with repeated nasal bleeding,
mucocutaneous telangiectasia on tongue and nose, multiple
arteriovenous malformations (AVMs) (lung and liver) and
family history and was being followed up. One year before
presentation, she had developed heart failure with lower
limb oedema and was treated with diuretics at another hos-
pital. She had also undergone coil embolization for pulmon-
ary haemorrhage due to pulmonary AVMs at a general
hospital six months previously. However, she experienced
persistent dyspnoea and was diagnosed with pulmonary
hypertension (PH). Despite speciﬁc treatment of PH with
bosentan, sildenaﬁl, and dobutamine, no improvement was
noted in her condition. Following this, she was referred to
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our centre, for specialised treatment of PH. She was in
World Health Organization functional class IV and had dys-
pnoea at rest. Her oxygen saturation was 97% with high
ﬂow nasal oxygen support. We performed a right heart cath-
eterization to assess her haemodynamic status. Her mean
pulmonary arterial pressure was 38mm Hg with a pulmon-
ary capillary wedge pressure of 10mmHg and a right atrial
pressure of 22mm Hg. Her cardiac output was 9.0 L/min,
and her pulmonary vascular resistance was 3.2 Wood units
(Fig. 1a). Oxygen sampling by catheter revealed an increase
in oxygen saturation in the inferior vena cava from 61 to
91% between the supra- and the infra-hepatic veins. As
shown in Fig. 1b and c, a time-dependent change was
observed in the morphology of the liver AVMs on computed
tomography scans. The suspicion of extensive proliferation
of AVMs was conﬁrmed by contrast-enhanced computed
Fig. 1. Haemodynamic data pre- and post-liver transplantation and arteriovenous malformations in the liver. A significant improvement in
haemodynamic parameters was observed after liver transplantation compared to pre-transplant values (a). Compared with one year previously
(b), low-density areas in the liver had enlarged on computed tomography scan indicating worsening of arteriovenous malformations (c). Contrast-
enhanced computed tomography and angiography shows major shunt caused by arteriovenous malformations in the liver (d and e).
PH: pulmonary hypertension; PCWP: pulmonary capillary wedge pressure; PAP: pulmonary arterial pressure; RAP: right atrial pressure; O2:
oxygen; SVC: superior vena cava; IVC: inferior vena cava; Qp: pulmonary blood flow; Qs: systemic blood flow.
*Haemodynamic data were adjusted because right heart catheter in the referred patient was performed under oxygen inhalation and the
continuous injection of dobutamine 3g.
yPAP is presented as systolic/diastolic (mean) pulmonary artery pressure.
zCardiac output is calculated using the average oxygen saturation in SVC and IVC, inferior to the hepatic vein as mixed venous oxygen saturation.
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tomography angiography (Fig. 1d and e). Based on these
ﬁndings and haemodynamic data, we considered the persist-
ence of PH to be due to extreme arteriovenous shunt in the
liver through the AVMs. Although previous study had
reported that bevacizumab could be an eﬀective treatment
for HHT patients with liver AVMs, it was not approved in
Japan.1 Following discussions with hepatologists and trans-
plant surgeons, we adjudged that liver transplantation (LT)
was essential for the treatment of this condition. She was
registered as an LT recipient, with a requirement for urgent
LT. In the meantime, we considered that the high ﬂow
through the liver also results in elevated central mixed
venous saturations that mimic those seen with atrial septal
defects and other large intra-cardiac left-to-right shunts.
Thereafter, we recalculated her haemodynamics using the
average oxygen saturation in superior and inferior vena
cava, inferior to the hepatic vein. By mixed venous oxygen
saturation 61%, we estimated that her actual systemic
output was reduced with 2.5L/min. As per the results, we
considered that more PH-speciﬁc therapy could increase her
actual output and decrease her pulmonary arterial pressure
that reduces her perioperative risk during LT, whereas it
involved taking risks to increase AV shunt ﬂow. Hence,
we decided to switch PAH drug. Simultaneously, we also
administered increasing diuretics to reduce any AV shunt
ﬂow. However, no signiﬁcant improvement was observed
in her condition even after the initiation of heart failure
and PH-speciﬁc therapy (Fig. 1a). Eleven months after the
initial presentation, she underwent a successful cadaveric
LT. Intraoperative monitoring revealed a dramatic reduc-
tion in the central venous pressure from 21 to 4mmHg after
LT. Postoperative right heart catheterization revealed a
remarkable haemodynamic improvement (Fig. 1a). Her
symptoms improved to World Health Organization func-
tional class I. She was continued on treatment with tadalaﬁl
and is being followed up regularly.
Discussion
In this case report, we describe the haemodynamic changes
before and after speciﬁc treatment for PH and after LT in a
patient with HHT. Detailed hemodynamic data were not
presented in previous reports.2,3 HHT or Rendu-Osler-
Weber syndrome is a systemic vascular disease leading to
the formation of AVMs in the nose, mouth, brain, lungs,
liver, gastrointestinal tract, and the skin.4 Various mutations
in genes – such as ENG, encoding endoglin, and ACVRL1,
encoding activin receptor-like kinase – are frequently asso-
ciated with HHT. Such mutations are components of the
receptor complexes for growth factors of the transforming
growth factor superfamily. Hence, mediated angiogenic fac-
tors such as the vascular endothelial growth factor are
believed to be involved in the expression of AVMs.1,4
A signiﬁcant variation exists among patients in the AVM
phenotype; however, the associated brain and pulmonary
lesions lead to substantial morbidity and mortality.
HHT is sometimes complicated with PH. There are some
mechanisms for the development of PH in patients with
HHT. PH commonly occurs due to a high output caused
by AVMs in organs such as the liver, frequently complicated
by left heart failure. Rarely, pulmonary arterial hyperten-
sion may be due to pulmonary vascular angiopathy.2 In
addition, HHT patients with the setting of liver cirrhosis
and portal hypertension may cause portopulmonary hyper-
tension. In our patient, major arteriovenous shunting was
observed through AVMs in the liver with a mild increase in
the pulmonary vascular resistance and left heart failure.
Hence, we considered extensive shunt through AVMs in
the liver to be the mechanism of causation of PH. Hence,
LT was essential to treat PH associated with HHT in our
patient.5 A previous report suggested that high pulmonary
arterial pressure, especially >35mm Hg, is a signiﬁcant peri-
operative risk factor for LT in patients with portopulmon-
ary hypertension.6 Fortunately, our patient did not have
severe but moderate elevation in pulmonary arterial pres-
sure, thus enabling successful LT. Although a signiﬁcant
improvement was noted in her clinical condition postopera-
tively, she requires careful follow-up for signs of worsening
systemic vascular abnormality.
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